BMY vs KPTI
BMY: Bristol Myers Squibb is a leading biopharmaceutical company specializing in advanced oncology, immunology, and cardiovascular therapies using diverse modalities like biologics and CAR-T cell technology. KPTI: Karyopharm is a clinical-stage oncology company commercializing XPOVIO, a first-in-class XPO1 inhibitor for multiple myeloma, with ongoing trials in myelofibrosis and endometrial cancer.
Side-by-side fundamentals
| Metric | BMY | KPTI | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $60.76 | $7.18 | |
| Market cap as of 2026-07-23 | $124.9B | $178M | |
| P/E as of 2026-07-23 | 20.91 | n/a | |
| PEG as of 2026-07-23 | -4.29 | -0.04 | BMY lower |
| Net margin as of 2026-07-23 | +12.3% | -129.0% | BMY higher |
| Gross margin as of 2026-07-23 | +53.7% | +96.0% | KPTI higher |
| Operating margin as of 2026-07-23 | +17.1% | -97.0% | BMY higher |
| ROE as of 2026-07-23 | +41.6% | -182.4% | BMY higher |
| ROA as of 2026-07-23 | +8.7% | -176.9% | BMY higher |
| Debt / equity as of 2026-07-23 | 2.22 | 3.78 | BMY lower |
| Revenue growth (YoY) as of 2026-07-23 | +1.8% | +6.3% | KPTI higher |
| Revenue CAGR (3y) SEC XBRL | +1.4% | -2.4% | BMY higher |
| Dividend yield as of 2026-07-23 | +4.1% | n/a | |
| Dividend streak (yrs) SEC XBRL | 5 | n/a | |
| Beta as of 2026-07-23 | 0.23 | 0.89 | |
| 1-year return as of 2026-07-22 close | +26.5% | +84.6% | KPTI higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.